Effect of long-term supplementation of low molecular weight chitosan oligosaccharide (GO2KA1) on fasting blood glucose and HbA1c in db/db mice model and elucidation of mechanism of action

BMC Complementary and Alternative Medicine

Volumn 14, Issue , 2014, Pages

  Kim, Jong Gwan ^a   Jo, Sung Hoon ^b   Ha, Kyoung Soo ^b   Kim, Sung Chul ^a   Kim, Young Cheul ^c   Apostolidis, Emmanouil ^d   Kwon, Young In ^b  

^a Kunpoong Bio Co Ltd   (South Korea)

^b Hannam University   (South Korea)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d FRAMINGHAM STATE UNIVERSITY   (United States)

Author keywords

Blood glucose; Glucosidase inhibitors; GO2KA1; Low molecular chitosan oligosacharide; Pre diabetes; Type 2 diabetes

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; CHITOSAN DERIVATIVE; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLUCOSE; GO 2KA 1; GO2KA1; HEMOGLOBIN A1C; MESSENGER RNA; OLIGOSACCHARIDE; SUCRASE; SUCRASE ISOMALTASE; UNCLASSIFIED DRUG; CHITOSAN OLIGOSACCHARIDE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DIET SUPPLEMENTATION; DRUG HYDROLYSIS; DRUG MECHANISM; ENZYMATIC ASSAY; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IN VITRO STUDY; INTESTINE; LONG TERM CARE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL TISSUE; CARBOHYDRATE DIET; CECUM; CHOLESTEROL BLOOD LEVEL; ENZYME INHIBITION; HEMOGLOBIN BLOOD LEVEL; HYDROLYSIS; SUPPLEMENTATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CHITOSAN; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; EATING; GLYCOSIDE HYDROLASES; HEMOGLOBIN A, GLYCOSYLATED; HYPERGLYCEMIA; INTESTINES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OLIGOSACCHARIDES; PREDIABETIC STATE;

EID: 84904774170     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-14-272     Document Type: Article

References (25)

1. Center for Disease Control. 2011, http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf.
2. James RG. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2002, 25:s5-s20.
3. World Health Organization. http://www.who.int/mediacentre/factsheets/fs312/en/index.html.
4. American Diabetes Association. http://www.diabetes.org/diabetes-basics/diagnosis/?loc=DropDownDB-diagnosis.
5. Hanefeld M. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc Diabetol 2007, 6:20.
6. Jenkins DJ, Taylor RH, Goff DV, Fielden H, Misiewicz JJ, Sarson DL, Bloom SR, Alberti KG. Scope and specificity of acarbose in slowing carbohydrate absorption in man. Diabetes 1981, 30:951-954.
7. Haffner SM. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev 1998, 19:583-592.
8. Di Carli MF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 2003, 41:1387-1393.
9. Puls W, Keup U, Krause HP, Thomas G, Hoffmeister F. Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia. Naturwissenschaften 1977, 64:536-537.
10. Martin A, Montgomery P. Acarbose: an alpha-glucosidase inhibitor. Am J Health-Syst Pharm 1996, 53:2277-2290.
11. Andlauer W, Furst P. Special characteristics of non-nutrient food constituents of plants-phytochemicals. Introductory lecture. Int J Vitam Nutr Res 2003, 73:55-62.
12. Apostolidis E, Kwon YI, Shetty K. Potential of cranberry-based herbal synergies for diabetes and hypertension management. Asia Pac J Clin Nutr 2006, 15:433-441.
13. Kwon YI, Vattem DA, Shetty K. Evaluation of clonal herbs of Lamiaceae species for management of diabetes and hypertension. Asia Pac J Clin Nutr 2006, 15:107-118.
14. Kwon YI, Apostolidis E, Kim YC, Shetty K. Health benefits of traditional corn, beans, and pumpkin: in vitro studies for hyperglycemia and hypertension management. J Med Food 2007, 10:266-275.
15. Kim MS, You HJ, You MK, Kim NS, Shim BS, Kim HM. Inhibitory effect of water-soluble chitosan on TNF-alpha and IL-8 secretion from HMC-1 cells. Immunopharmacol Immunotoxicol 2004, 26:401-409.
16. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 2004, 146:1-12.
17. Nishimoto N, Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004, 4:386-391.
18. Huang R, Mendis E, Kim SK. Improvement of ACE inhibitory activity of chitooligosaccharides (COS) by carboxyl modification. Bioorg Med Chem 2005, 13:3649-3655.
19. Kondo Y, Nakatani A, Hayashi K, Ito M. Low molecular weight chitosan prevents the progression of low dose streptozotocin-induced slowly progressive diabetes mellitus in mice. Biol Pharm Bull 2000, 23:1458-1464.
20. Kim YCK SH, Yoon SP, Kim JW. Reducing effect of chitosan oligosaccharide on postprandial blood glucose level in Koreans. J Chitin and Chitosan 2009, 14:107-111.
21. Jo SH, Ha KS, Moon KS, Kim JG, Oh CG, Kim YC, Apostolidis E, Kwon YI. Molecular weight dependent glucose lowering effect of low molecular weight chitosan oligosaccharide (GO2KA1) on postprandial blood glucose level in SD rats model. Int J Mol Sci 2013, 14:14214-14224.
22. Dahlqvist A. Method for assay of intestinal disaccharidases. Anal Biochem 1964, 7:18-25.
23. Krentz A, Bailey C. Oral antidiabetic agents. Drugs 2005, 65:385-411.
24. Dehghan-Kooshkghazi M, Mathers JC. Starch digestion, largebowel fermentation and intestinal mucosal cell proliferation in rats treated with the a-glucosidase inhibitor acarbose. Br J Nutr 2004, 91:357-365.
25. Kim GN, Kwon YI, Jang HD. Mulberry leaf extract reduces postprandial hyperglycemia with few side effects by inhibiting a-glucosidase in normal rats. J Med Food 2011, 14:712-717.